OAC
CCCC icon

OMERS Administration Corp’s C4 Therapeutics CCCC Stock Holding History

OMERS Administration Corp’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-59,700
Closed -$157K – 956
2026
Q1 		$157K Sell
59,700
-58,000
-49% -$137K ﹤0.01% 954
2025
Q4 		$225K Buy
+117,700
New +$279K ﹤0.01% 890

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

OMERS Administration Corp's CCCC Position: Q2 2026 in Review

OMERS Administration Corp sold out of C4 Therapeutics (CCCC) in Q2 2026, closing a stake of 59,700 shares — an estimated $157K sold.

OMERS Administration Corp first reported a position in CCCC in Q4 2025 and held it in 2 quarters. The position peaked at $225K in Q4 2025. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • OMERS Administration Corp reported no remaining C4 Therapeutics position as of Q2 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 59,700 C4 Therapeutics shares in Q2 2026, an estimated $157K.
  • OMERS Administration Corp first reported a position in C4 Therapeutics in Q4 2025 and held it in 2 quarters.
  • OMERS Administration Corp's C4 Therapeutics position peaked at $225K in Q4 2025.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on OMERS Administration Corp's 13F filing for Q2 2026, filed 13 Aug 2026.